Physician profile
Michael C Yu
NPI 1366581290
$3,175.15
in general payments reported to CMS, 2019-2025
32 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $237 · 2022: $256 · 2023: $782 · 2024: $544 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825 · Education: $95.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.03 |
| Education | $95.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $794.11 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $289.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $271.34 | 2020-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $250.05 | 2023-2025 | |
| Glaxosmithkline, LLC. | $242.03 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $169.42 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $121.37 | 2025 | Symbravo |
| Lilly USA, LLC | $112.90 | 2023-2024 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $97.76 | 2019-2023 | |
| Sanofi Pasteur INC. | $83.08 | 2020-2024 | |
| Exact Sciences Corporation | $69.25 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $68.51 | 2022 | |
| Amarin Pharma, INC. | $57.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.79 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.41 | 2019-2023 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $49.72 | 2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $43.68 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.50 | 2025 | Qelbree |
| Intra-Sana Laboratories | $33.41 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Bayer Healthcare Pharmaceuticals INC. | $33.13 | 2022-2023 | |
| Phadia US INC. | $29.71 | 2025 | Immunocap |
| Gilead Sciences, INC. | $29.13 | 2019 | |
| Phathom Pharmaceuticals, INC. | $27.56 | 2024 | Voquezna |
| Abbvie INC. | $25.00 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $19.10 | 2019 | |
| Shire North American Group INC | $19.01 | 2019 | |
| Vertiflex, INC. | $18.35 | 2019 | |
| Redhill Biopharma INC. | $16.03 | 2020 | |
| Allergan, INC. | $15.88 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2024 | Zoryve |
| Genentech USA, INC. | $13.54 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.